Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

× No keyword cloud information.

61 in total

Review 1. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.

Authors: Sabina Sandigursky; Adam Mor
Journal: Curr Rheumatol Rep Date: 2018-09-06 Impact factor: 4.592

2. In Reply.

Authors: Blake Warner; Alan Baer
Journal: Oncologist Date: 2019-11-06

3. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors: Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal: Oncologist Date: 2019-10-10

4. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors: Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal: Oncologist Date: 2019-10-10

5. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Authors: Emily Hinchcliff; David Hong; Hung Le; Gary Chisholm; Revathy Iyer; Aung Naing; Patrick Hwu; Amir Jazaeri
Journal: Gynecol Oncol Date: 2018-10-24 Impact factor: 5.482

6. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.

Authors: Marije S Koks; Gurbey Ocak; Britt B M Suelmann; Cornelia A R Hulsbergen-Veelken; Saskia Haitjema; Marieke E Vianen; Marianne C Verhaar; Karin A H Kaasjager; Meriem Khairoun
Journal: PLoS One Date: 2021-06-08 Impact factor: 3.240

7. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.

Authors: Ha Nguyen; Komal Shah; Steven G Waguespack; Mimi I Hu; Mouhammed Amir Habra; Maria E Cabanillas; Naifa L Busaidy; Roland Bassett; Shouhao Zhou; Priyanka C Iyer; Garrett Simmons; Diana Kaya; Marie Pitteloud; Sumit K Subudhi; Adi Diab; Ramona Dadu
Journal: Endocr Relat Cancer Date: 2021-06-02 Impact factor: 5.678

Review 8. Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC).

Authors: Long-Sheng Lu; Yen-Wen Wu; Joseph Tung-Chieh Chang; Wei-Ting Chang; Ting-Hsing Chao; Helen Hai-Wen Chen; Yu-Jen Chen; Kai-Hung Cheng; Wen-Lin Hsu; Chung-Lieh Hung; Sung-Hsin Kuo; Ji-An Liang; Hung-Ju Lin; Ping-Yen Liu; Wen-Shan Liu; Yen-Wen Liu; Pei-Wei Shueng; Chao-Yung Wang; Charles Jia-Yin Hou; Jeng-Fong Chiou
Journal: Acta Cardiol Sin Date: 2022-01 Impact factor: 2.672

9. Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence.

Authors: Yihang Qi; Lin Zhang; Zhongzhao Wang; Xiangyi Kong; Jie Zhai; Yi Fang; Jing Wang
Journal: Front Pharmacol Date: 2021-06-29 Impact factor: 5.810

10. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use.

Authors: Sean C Dougherty; Alia C Lynch; Richard D Hall
Journal: Clin Case Rep Date: 2021-06-22